In DaVINCI , a randomised phase II trial , patients with advanced colorectal cancer were randomly allocated to : Combination therapy ( FOLFIRI ) , irinotecan ( 180 mg/m ( 2 ) IV over 90 min , day 1 ) , 5-fluorouracil ( 400mg/m ( 2 ) IV bolus and 2400 mg/m ( 2 ) by 46-hour infusion from day 1 ) and folinic acid ( 20mg/m ( 2 ) IV bolus , day 1 ) , 2-weekly ; or Single-agent , irinotecan ( 350 mg/m ( 2 ) IV over 90 min ) , 3-weekly .
